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Background:There is growing evidence that human immunodeficiency virus (HIV)-infected
women might have a different human papillomavirus (HPV) type distribution in cervical dys-
plasia specimens as compared to the general population.This has implications for primary
prevention.
Objective: We aimed to obtain preliminary data on the HPV genotypes prevalent in histo-
logical samples of HIV-infected women with cervical intraepithelial neoplasia (CIN) 3/CIS
of the cervix in Miami, FL, USA.
Methods: Retrospective data were collected on HIV-infected women referred to the Univer-
sity of Miami-Jackson Memorial Hospital colposcopy clinic between years 2000 and 2008.
The histology slides of CIN 3/CIS biopsies underwent pathological review and sections
were cut from these archived specimens for HPV DNA extraction. HPV genotyping was
then performed using the GeneSquare™ HPV genotyping assay. We report on our first set
of 23 samples.
Results: Eight high-risk HPV types were detected.Types in decreasing order of frequency
were 16, 35, 45, 52, 59, 31, 58, and 56. Most cases had multiple infections. HPV type 16
was the most common (45%) followed by HPV-35 and -45 with equal frequency (40%). No
samples contained HPV-18.
Conclusion: Our preliminary results suggest that cervical dysplasia specimens of HIV-
infected women more likely (55%) contain non-16 and -18 high-risk HPV types. We show
that this held true for histologically confirmed severe dysplasia and carcinoma-in situ. Epi-
demiological studies guide vaccine development, therefore HPV type prevalence in CIS and
invasive cervical cancer among HIV-infected women should be more rigorously explored
to ensure that this highly vulnerable population receives appropriate primary prevention.
Keywords: HPV, HIV, CIN, cervical cancer
INTRODUCTION
Epidemiological studies demonstrate that high-risk human papil-
lomavirus (HR-HPV) genotypes are the necessary cause of 99.7%
of cervical cancer. Seven of them [human papillomavirus (HPV)-
16, -18, 45, 31, 33, 52, 58] account for nearly 90% of all cervical can-
cer cases in the general population worldwide with little regional
variation (1). HPV types 16 and 18 together account for the great
majority (70%) of cervical carcinomas in the general population.
HPV-16 and -18 are far less common in low grade pre-cancerous
lesions. Rather, their prevalence increases with grade of cervical
dysplasia. However, there is growing evidence that human immun-
odeficiency virus (HIV)-infected women might have a different
HPV type distribution in cervical dysplasia specimens as com-
pared to the general population (2). When HIV-infected women
are infected with HR-HPV, the natural history of the HPV infec-
tion and subsequent carcinogenesis is different when compared
to non-HIV-infected women. Specifically, HIV-infected women
with HR-HPV progress more rapidly to high-grade dysplasia and
invasive cervical cancer; the dysplasia is more likely to recur after
treatment; and when invasive cancer does develop it responds
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poorly to standard treatment (2). Because extensive epidemiolog-
ical studies were instrumental in determining the HR-HPV types
commonly found in invasive cervical cancer thereby guiding the
development of the current HPV vaccines, it would be equally
important to perform the same rigorous epidemiological inves-
tigation for HIV-infected women. The two FDA-approved HPV
vaccines protect against HR-HPV-16 and 18 while one of them
also protects again HPV types 6 and 11 which are not oncogenic
but are associated with genital warts. As previously mentioned,
HIV-infected women with abnormal cervical cytology specimens
tend to be infected with non-16 and -18 HR-HPV types, such as 51,
52, 53, 56, and 58, but the most prevalent type appeared to differ
by geographic region (Table 1) (2). One criticism of these studies
on HIV-infected women is that the samples contained little or no
invasive cancer cases. Also, only cytological (Pap smear) diagnoses
of low grade intraepithelial lesions (LGSIL) or rarely, high-grade
squamous intraepithelial lesions (HGSIL) were obtained. HGSIL
is a cytological diagnosis, which groups together moderate and
severe dysplasia. To have clinical relevance, all cytology results
must be confirmed through biopsies to obtain a histological diag-
nosis of grade of dysplasia or cervical intraepithelial neoplasia
(CIN). These diagnoses are defined as follows: CIN 1 (mild dys-
plasia), CIN 2 (moderate dysplasia), and CIN 3 (severe dysplasia
and carcinoma-in situ). This histological confirmation was not
performed in previously reported studies on HPV type prevalence
in HIV-infected women (2).
There is sufficient clinical trial data to show that there is modest
cross-protection by the current HPV-bivalent (16/18) and quadri-
valent (6/11/16/18) vaccines against additional HR-HPV types
(9–11). The L1 protein, a late gene product of the HPV, can auto-
assemble into an empty (non-DNA containing) virus like particle
(VLP). These L1 VLPs are morphologically close to authentic HPV
virions except that they lack the viral genome. VLPs possess the
conformational epitopes required for the induction of neutraliz-
ing antibodies. Specifically, the antibody responses are typically
generated against epitopes found on the external loops of the L1
protein present on the outer VLP surface (12). Protection against
HPV requires the full-length protein (intact VLP). Protection is
also HPV type-specific with the L1 VLPs. L2, a minor capsid pro-
tein, was also investigated as a vaccine candidate and L2-VLPs
were found to be less efficient than L1, but were able to induce
HPV type cross-protective antibodies (13). This may in part relate
to differing L1 epitopes of different HPV types. For example, the
amino-acid sequence of HPV-16 L1 shares greatest homology with
HPV-31 L1 and HPV-35 L1 than with HPV-33 L1 (83.1, 82.8,
and 79.7% amino-acid sequence identity, respectively) (14). How-
ever, because neutralizing epitopes of HPVs are conformation-
dependent, their amino-acid composition and surface localization
have not been fully characterized. Work by Combita et al. (15)
showed that linear epitopes within the L1 protein could induce
cross-neutralization; however, the cross-neutralization induced
by L1 VLPs represents <1% of the neutralizing activity induced
by dominant conformational epitopes, which is unlikely to con-
fer sufficient cross-protection in vivo. With the overwhelming
evidence that the current HPV vaccines cannot offer sufficient
cross-protection with many other HR-HPV types, it is imperative
that the most common types associated with malignancy in HIV,
Table 1 | Common HPV genotypes in HIV-infected women –
summary (2).
Studyc HPV types more common than 16
Palefsky et al. (3) 53b, 58
Levi et al. (4) 51, 18
Levi et al. (5) a
La Ruche et al. (6) a
Luque et al. (7) 56, 53b
Sahasrabuddhe et al. (8) 52, 58
a16 was most prevalent in this study.
bHPV type 53 is considered probably carcinogenic by the Munoz (1) classification.
cReferences from Ref. (3–8).
after HPV-16 and -18 be determined. Also, given that HIV-infected
women are at greatest risk of developing HPV-related disease and
dying from cervical cancer, it would be important to know whether
the HPV type distribution in this patient population is similar to
that of the general population thereby justifying the use of current
HPV vaccines in HIV-infected women. Furthermore, the Hepatitis
B vaccine trials showed that HIV-infected women do benefit from
vaccines against oncogenic viruses with a 50–55% sero-conversion
rate. The vaccine is more efficacious in individuals with higher
CD4 cell count and low HIV viral loads (16). Nevertheless, Hepati-
tis B vaccines are recommended for HIV-infected individuals and
if the HPV vaccine proves to be effective in this population, we
can expect that the vaccine will become part of the vaccination
protocol for this group as well.
Meta-analyses have shown that, in the general population,
many HR-HPV types are common in low grade cervical dysplasias
however, as the grade of dysplasia increases HPV types 16 and 18
predominate. This follows a fairly linear upward trend. Similarly, as
the grade of dysplasia increases, the other HR-HPV types become
less common following a downward trend (Figure 1). High-grade
dysplasia or CIN 3 is the most immediate pre-cursor to inva-
sive cervical cancer. The HPV types found in CIN 3 are similar
to those found in cervical cancer. Furthermore, CIN 2 and lesser
grade lesions have poor diagnostic reproducibility and have less
positive predictive value than CIN 3 (17). Our aim was to obtain
histological specimens with diagnosis of CIN 3 from HIV-infected
women for HPV genotyping with the ultimate goal of providing
preliminary evidence on the types of HR-HPV associated with
malignant transformation in this population.
MATERIALS AND METHODS
After obtaining IRB consent, retrospective de-identified clinical
data were collected on 510 HIV-infected women with abnormal
Pap smears seen at the University of Miami-Jackson Memorial
Hospital (UM-JMH) colposcopy clinic between 2000 and 2008
(Figure 2). This clinic evaluates women by performing Pap smears,
colposcopies, and biopsies (when visual abnormalities are found)
of the cervix, vulva, and anus every 6 months until they have
normal colposcopic and histological results for at least 1 year or
undergo surgical treatment for a high-grade pre-cancerous lesion.
Because HIV-infected women under our care are followed closely
(every 6 months) with regards to HPV-related disease, those that
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FIGURE 1 | Human papillomavirus type prevalence in different grades
of dysplasia pooled estimates from all continents, general population
(22, 23).
FIGURE 2 | Selection flowchart.
are compliant with treatment rarely progress to invasive cervical
cancer. In fact, those with cervical cancer in the database were
well known for their non-compliance with follow-up or were new
patients with a pre-existing cervical cancer. Therefore, because of
the rarity with which we see invasive cervical cancer in the patients
followed at the UM-JMH colposcopy clinic and the fact that CIN
3 is considered to have positive predictive value, we decided to
obtain genotyping data on CIN 3 specimens from these women
to allow for a larger sample size than would have been possible by
targeting invasive cancers.
Fifty patients (74 events) were diagnosed with CIN 3 (severe
dysplasia/carcinoma-in situ) by cervical biopsies. Twenty patients
had samples that were considered probably too old for success-
ful DNA extraction and were excluded. Samples were limited to
one event per patient using the case with the most severe pathol-
ogy. All slides underwent central Gynecologic Pathology review.
There were 24 of 30 remaining histology slides that were con-
firmed CIN 3 while the others were down-graded to CIN 2. The
corresponding paraffin-embedded blocks of the CIN 3 were pulled
and two 20-micron sections were cut from each block. DNA was
extracted from these sections using the Ambion™ Recover All kit
as per manufacturer’s instructions. We were able to successfully
extract DNA for HPV genotyping on 23 samples. Clinical data
on the final 23 cases were also obtained including patient demo-
graphics, cytological/histological results, as well as CD4 counts
and HIV-1 viral load. After DNA was extracted from paraffin
sections, we performed Nanodrop analysis to check concentra-
tion/ratio of DNA. This was followed by analysis of DNA on
an Agilent™ Bioanalyzer chip to assess quality. HPV genotyp-
ing of these samples was performed using the Genesquare™ kit
developed by Kurabo Industries LTD (Bio-medical Department,
Kurabo Industries LTD., Osaka, Japan), which tests for 23 HPV
types including all high-risk types and some low risk types. This
kit uses multiplex PCR assays with HPV type-specific primers.
We chose this PCR-sequencing method because it offers sensitive
detection of HPV types at a lower cost and with increased pro-
cessing speed than the standard Roche Linear array. Furthermore,
there is no cross-hybridization because HPV type-specific primers
are used as compared to the Roche method, which uses the L1 con-
sensus primer (high-homology region). However, the Genesquare
assay has not yet been validated in a large trial.
STATISTICAL METHODS
De-identified study data were stored and managed in Microsoft
Excel. SAS version 9.2 for windows (SAS Institute Inc., Cary, NC,
USA) was used for statistical analysis. Descriptive statistics such as
mean, standard deviation, median, first and third quantiles were
reported for patients’ age and some of patients’ clinical charac-
teristics, such as number of HPV infections, viral load, and CD4
count. Frequencies and percentages were calculated for charac-
teristics such as race/ethnicity, grade of dysplasia, treatment, and
recurrence of dysplasia. One-sample exact binomial test was used
to test the differences in HPV genotype prevalence in cervical
lesion of women between HIV-infected women and the general
population reported. Type-I error rate is set to 5%.
RESULTS
In this sample (n= 23), 83% of women were African-American or
Haitian-American and 50% were age 40 or younger (Table 2).
Mean CD4 count was 193 (min; max: 15; 333). Mean Viral
Load was 6,982 (min; max: 24; 639,000). Three samples had no
detectable HPV DNA (or the DNA copies were below the assays’
threshold). Most cases had multiple infections with two to five
high-risk types in the same sample and a total of 43 HPV infec-
tions in the remaining 20 samples. Eight HR-HPVs were detected.
The types in decreasing order of frequency were 16, 35, 45, 52,
59, 31, 58, and 56 (Figure 3). Interestingly, HPV-16 was one of
few types to stand alone (six HPV-16, one HPV-31, one HPV-
59). HPV-16 was the most common (45%) per sample followed
by HPV-35 and HPV-45 with equal frequency (40%). None of
the samples contained HPV-18 (Table 3). All but one of the
HR-HPVs detected were from the alpha-9 or alpha-7 species – the
most carcinogenic among high-risk types (Table 4). Finally, 55%
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Table 2 | Patients’ characteristics (n=23).
Characteristics All, n(%)a
Age
Mean (StdDev) 37 (8)
Median (Q1; Q3) 40 (32; 41)
Min–max 18–52
Race/Ethnicity
African-American 14 (60.86)
Haitian 5 (21.74)
Latino 2 (8.70)
White 2 (8.70)
Grade of dysplasia
Severe dysplasia (CIN 3) 13 (56.52)
Carcinoma-in situ (CIS) 10 (43.48)
HPV-16/-18
HPV-16/-18 9 (45.00)
not HPV-16/-18 11 (55.00)
Not determined 3
Viral load count
Mean (StdDev) 6,982 (171,704)
Median (Q1; Q3) 2,344 (477; 24,700)
Min–max 24–639,000
Count ≤10,000 10 (62.50)
Count >10,000 6 (37.50)
CD4 count
Mean (StdDev) 193 (174)
Median(Q1; Q3) 146 (28; 315)
Min–max 15–533
Count ≥200 12 (60)
Count <200 8 (40)
an and percentages are presented unless otherwise specified; StdDev, standard
deviation; Q1: 25th%; Q3: 75th%.
of the samples contained HR-HPV types other than -16 or -18.
Specifically, HPV types 35, 45, 52, and 59 were significantly more
prevalent in high-grade lesions of HIV-infected women in Miami,
than in the high-grade lesions of women in the general popula-
tions (p< 0.05). However, the prevalence of HR-HPV types 16, 31,
56, and 58 were not significantly different than those in cervical
lesions of women in the general population.
DISCUSSION
In conclusion, we found that certain HR-HPV types that are con-
sidered relatively rare in high-grade cervical lesions of women in
the general population were actually more common in high-grade
lesions of HIV-infected women at the UM-JMH colposcopy clinic.
We also found that the most prevalent HPV types (16, 35, 45) in
these high-grade lesions among HIV-infected women at our insti-
tution differed from those of other HIV-infected women in other
geographic regions (Table 5).
Among the HPV types found in the HIV-infected population,
HPV types 52, 53, 58, and 56 are the most commonly cited. In
contrast, we found HPV-35, -16, and -45 to be the most common in
our samples and none had HPV-18. This might be explained by the
FIGURE 3 | Human papillomavirus genotype distribution (per infection)
in HIV-infected women.
Table 3 | Human papillomavirus types by grade of dysplasia.
Patient ID HPV-16/-18 HPV type Grade of dysplasia
1 No 35, 56 SD
2 No 45, 52 CIS
3 Yes 16 SD
4 – ND CIS
5 Yes 16, 35, 45 SD
6 No 35, 45 CIS
7 No 59 SD
8 No 35, 59 SD
9 No 31 SD
10 No 35, 45, 52 CIS
11 No 31, 45, 52, 59 SD
12 No 35, 59 CIS
13 Yes 16 CIS
14 Yes 16, 35, 45, 52 CIS
15 No 45, 52, 58 SD
16 Yes 16 SD
17 Yes 16 SD
18 No 31, 58, 59 CIS
19 Yes 16 CIS
20 Yes 16 SD
21 – ND SD
22 Yes 16, 35, 45, 52, 59 CIS
23 – ND SD
ND, non-detected (DNA viral copies below threshold for assay).
SD, severe dysplasia.
CIS, carcinoma-in situ.
fact that all specimens were of squamous histology while HPV-18
is more commonly found in adenocarcinomas of the cervix (18).
In our sample, 95% (19/20) of the HPV types detected belonged
to either alpha-9 or alpha-7 species. The alpha species of HPV are
those subgroups of the virus that infect the genito-anal epithelium
(19). The population-based results from Schiffman’s Guanacaste
Project in Costa Rica (2005) demonstrate wide variability in HPV
type-specific prevalence. They also found that the more likely a
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Table 4 |Types by species and single infection.
HPV type Frequency
(n, % per 20 samples)
Alpha
species
n, % single
infection
16 9, 45 9 6, 75
31 3, 15 9 1, 12.5
35 8, 40 9 0
45 8, 40 7 0
52 6, 30 9 0
58 2, 10 9 0
59 6, 30 7 1, 12.5
56 1, 5 6 0
Table 5 | Human papillomavirus genotype prevalence (worldwide) in
HGSIL compared to HIV+ in Miami.
HPV genotype HGSIL (%)a HIV HGSIL(%)
16 45.3 45
18 6.9 –
45 2.3 40c
33 7.3 –
31 8.6 15
58 7.0 10
52 5.1 30c
35 3.8 40c
59 0.8 30c
53 –b –
51 3.6 –
66 1.9 –
39 2.0 –
6 2.2 –
56 2.9 5
aSmith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in
cervical lesions: a meta-analysis update.
ICC: invasive cancer.
bThe updated meta-analysis by Smith did not include type 53 in their publication
of HGSIL unlike the previous publication by this group with regards to LGSIL and
ICC.
cp-Value<0.05, which was calculated by one-sample exact binomial test for com-
paring our sample prevalence with the prevalence reported in (b) HGSIL and in (c)
ICC. P-value <0.05 implies that the HPV genotype prevalence in cervical lesions
of HIV-infected women in Miami, FL, USA is SIGNIFICANTLY different than the
HPV genotype prevalence in cervical lesions of women in the general population.
SIGNIFICANT HPV types are 35, 45, 52, and 59. NOT SIGNIFICANT HPV types
are 16, 31, 56, and 58, i.e., p-value ≥0.05, i.e., the HPV genotype prevalence in
cervical lesions of HIV-infected women in Miami, FL, USA is NOT SIGNIFICANTLY
different than the HPV genotype prevalence in cervical lesions of women in the
general population.
viral type was to persist, the more prevalent it was in the pop-
ulation (Spearman correlation coefficient 0.46, p-value= 0.005).
In that same article, the most carcinogenic HPV types concen-
trated in species alpha-9 and alpha-7 were distinguished by ele-
vated risk of progression given persistence, rather than persistence
alone. Alpha-5 and alpha-6 species were also at elevated risk of
progression given persistence (20). The fact that the majority of
the HPV types found in CIN 3 of HIV-infected women in Miami,
FL, USA belong to the alpha-9 and alpha-7 species further sup-
ports the findings of Schiffman and colleagues. Specifically, these
authors reported that the alpha-9 and alpha-7 species were the
most carcinogenic given persistence (20). The presence of highly
carcinogenic HPV in our cervical samples of severe dysplasia and
carcinoma-in situ is not surprising. Despite their high oncogenic
potential, however, these other HPV types are less prevalent than
HPV-16 and -18 in the general population. Nothing currently
exists in the literature that explains why HIV-infected women are
more susceptible to these typically less prevalent types. It is possi-
ble that despite the oncogenic potential of these other HPV types
(35, 45, 52, and 59) they are not able to evade the immune sys-
tem as efficiently as HPV types 16 and 18 except in HIV-infected
individuals who are immunocompromised. To test this hypothesis
regarding immunocompromised status and link with HPV type
prevalence, a simple genotyping study in immunocompromised
women not due to HIV (such as chronic steroid use, leukemia,
renal transplant recipients) could be evaluated.
Usually HIV-infected women are infected with multiple types
of HPV concurrently. The great majority of cases in our sample did
in fact contain multiple HR-HPV types. One sample had as high
as five concurrent HPV types simultaneously. While a few sam-
ples (n= 8) contained a single infection. HPV-16 accounted for
75% of these single infections (Table 4). These findings are both
interesting and hypothesis generating. It is possible that the other
HPV types act synergistically to promote carcinogenesis and are
less efficient at carcinogenesis as single infections while HPV-16
is capable of inducing malignant transformation more efficiently
than the others as a single infection. The activity of HPV oncopro-
teins E6 and E7 (largely responsible for malignant transformation
of cervical cells) from different HPV types should be compared
with regards to their likelihood of inducing carcinogenesis. Yet,
another explanation is that the immune system is so compromised
that it allows any pathogen to infect and persist within the human
host as is seen with opportunistic infections in HIV-infected indi-
viduals. To test this hypothesis, we would expect to see the rate
of multiple infections increase with decreasing CD4 count and
increasing HIV viral load. We did not observe this trend; how-
ever, our small sample precludes the ability to make a meaningful
comparison.
In contrast to other studies, we focused on high-grade lesions
as opposed to mostly low grade lesions. The limitation of the other
studies on HIV-infected women was that they used mostly cyto-
logical samples whose diagnoses were not always confirmed by
histological review. The strategy employed in this study is more
expensive and labor intensive than cytology alone, but also more
precise. Histologically diagnosed CIN 3 is considered as a high-risk
cervical cancer pre-cursor, and is an ideal source for HPV geno-
typing in terms of its high positive predictive value for progression
to invasive cervical cancer as well as the fact that it is associated
with the same HPV genotypes in the similar proportions as it
is associated with cervical cancer. CIN 2 and lesser grade lesions
have poor diagnostic reproducibility and have less positive predic-
tive value than CIN 3 (17). Because the cytological diagnoses of
HGSIL groups CIN 2 and CIN 3 together, the correlation of HPV
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types with HGSIL is not as precise as with histologically confirmed
severe dysplasia or CIN 3/CIS. Therefore, strength of our study is
that we used histologically confirmed CIN 3 lesions instead of
cytology alone. Given the uncommon incidence of invasive cer-
vical cancer in a HIV-positive population with access to health
care such as our patient group (21), we felt that the inclusion
of high-grade lesions would increase our sample size while pro-
viding appropriate HPV type prevalence estimates for high-grade
dysplasia (and extrapolates for invasive cervical cancer) in this
population (Table 5).
As seen in Figure 1, the prevalence of non-16/-18 HR-HPV
types decreases as the grade of dysplasia increases while the preva-
lence of HPV-16/-18 increases with grade of dysplasia in the
general population. In our sample, HPV-16 prevalence in high-
grade lesions was not different than that of the general population.
What was different was the relative increase in prevalence of other
HR-HPV types as compared to the general population in which
they usually decrease and are less prevalent than HPV-16/-18 in
higher grade lesions. One explanation is that HPV-16 continues
to be as carcinogenic in HIV with similar efficiency, but an advan-
tage is conferred to the other less efficient types thereby increasing
their prevalence in high-grade lesions. This advantage likely occurs
because the decreased vigilance of the immune system in these
women allows for less virulent strains to result in malignant trans-
formation as compared to their immunocompetent counterparts
in whom the more virulent strains such as HPV-16 prevail.
In summary, our study design was based on the positive predic-
tive value of CIN 3 lesions in predicting HPV genotypes in invasive
cervical cancer from the same population. Strength of our study
was the use of histological pathology review for all samples con-
firming the grade of the lesions. Our findings are consistent with
that of others who found rare HR-HPV types to be more com-
mon in dysplasia of HIV-infected women. In this pilot study, the
sample was small (n= 23), however, these preliminary results sup-
port the feasibility of retrospective HPV genotyping from archival
paraffin-embedded blocks in our lab as well as the need for further
research in this area. Because developing countries are known to
have higher rates of HIV than the developed world and HPV is
more aggressive in HIV-infected individuals, the highest potential
for global public health impact by a HPV vaccine would be con-
ferred by its effectiveness in the HIV-infected population or those
at risk of acquiring the infection. We are now planning to better
characterize differences between HIV-infected and HIV-negative
women in terms of their HPV type prevalence and their immunity
profiles with the goal of guiding the development of both thera-
peutic and prophylactic vaccines that would be effective not only
in the general population but also in the HIV-infected population.
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